Phase I study of BIVV001 in subjects with severe hemophilia A
Latest Information Update: 17 Jan 2023
At a glance
- Drugs Efanesoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
Most Recent Events
- 13 Dec 2022 Population Pharmacokinetic (PopPK) analysis performed by using blood samples from 5 clinical studies(NCT03205163, EudraCT 2018-001535-51, NCT04161495, NCT04759131 and NCT04644575) presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Results of a post hoc analysis is assessed the relationship between endogenous VWF antigen levels and efanesoctocog alfa half-life and clearance in patients with severe hemophilia A from the single- and repeat-dosing studies presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 23 Jun 2020 According to a Sanofi media release, positive phase 1 repeat dose study results were presented at the World Federation of Hemophilia Virtual Summit earlier this month.